Description
Multiple Sclerosis is a demyelinating degenerative disease that is rising in prevalence. Relapsing Remitting Multiple Sclerosis is a type of Multiple Sclerosis in which patients experience an onset of neurological symptoms followed by complete or partial recovery. Provided is a review of the efficacy and safety of Teriflunomide for the treatment of Relapsing Remitting Multiple Sclerosis using clinical studies, reviews, and comparative studies. The results show that Teriflunomide is one of the preferred medications prescribed for RRMS because of its ability to significantly reduce relapse rates, disability progression, and its' suppression of active inflammatory lesions. When considering the type and number of adverse events encountered with all treatments in addition to the efficacy, Teriflunomide becomes the clear choice.